Sandbox vidit5: Difference between revisions
Jump to navigation
Jump to search
Line 21: | Line 21: | ||
{{familytree | | | | E02 |-| E01 | | | | | | | |E01= Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease |E02=Yes}} | {{familytree | | | | E02 |-| E01 | | | | | | | |E01= Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease |E02=Yes}} | ||
{{familytree | | | | |!| | | |!| | | | | | | | }} | {{familytree | | | | |!| | | |!| | | | | | | | }} | ||
{{familytree | | | | F01 | | F02 | | {{familytree | | | | F01 | | F02 | | | | | | |F01= ❑ Give high flow supplemental oxygen (6-8 L/min) |F02=No }} | ||
{{familytree | | | | |!| | | |!| | | | | | | | }} | {{familytree | | | | |!| | | |!| | | | | | | | }} | ||
{{familytree | | | | |`|-|-| G01 | | G02 | | | |G01=Patient hypotensive despite epinephrine? |G02=Yes }} | {{familytree | | | | |`|-|-| G01 |-| G02 | | | |G01=Patient hypotensive despite epinephrine? |G02=Yes }} | ||
{{familytree | | | | | | | | |!| | | |!| | | | }} | {{familytree | | | | | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | | | | | H01 | | {{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<left> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </left> }} | ||
{{familytree | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | |!| | | |!| | | | }} | ||
{{familytree | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | I01 |-|-|'| | | |I01=Secondary therapy after epinephrine (evidence not clear) <br> H1 antihistaminics: <br> Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children | ||
---- | |||
H2 antihistaminics: <br> Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM }} | |||
{{familytree | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | | | | | | | | J01 | | | | | | |J01=Observe the patient for biphasic anaphylaxis <br> Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br> Provide auto-injectable epinephrine and action plan for future events at discharge }} | |||
{{familytree/end}} | {{familytree/end}} |
Revision as of 14:18, 17 January 2014
Management
Shown below is an algorithm summarizing the approach to [[disease name]].
Characterize the symptoms & signs: Skin, subcutaneous tissue and mucosa: ❑ Flushing, itching, urticaria, angioedema, rash, piloerection ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing Respiratory: Gastrointenstinal: Cardiovascular: Central nervous system: ❑ Anxiety, irritability ❑ Throbbing headache ❑ Altered vision and mental status | |||||||||||||||||||||||||||||||||
Consider alternative diagnosis: ❑ Acute asthma ❑ Anxiety/Panic attack ❑ Syncope | |||||||||||||||||||||||||||||||||
Remove patient from exposure/trigger | |||||||||||||||||||||||||||||||||
Do all 3 simultaneously ❑ Call for help ❑Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution Maximum dose 0.5 mg (adult) or 0.3 mg (child) Record the time of the dose and repeat it in 5-10 minutes, if needed or ❑ In patients with hypotension/cardiorespiratory arrest and those not responding: Intravenous epinephrine 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) Titrate based on clinical response or epinephrine side effects ❑ Place patient on back/comfortable position; elevate legs | |||||||||||||||||||||||||||||||||
Yes | Patient has one of the following? ❑ Respiratory distress ❑ Recieved repeated doses of epinephrine ❑ Asthma/other respiratory disease ❑ Co-existing cardiovascular disease | ||||||||||||||||||||||||||||||||
❑ Give high flow supplemental oxygen (6-8 L/min) | No | ||||||||||||||||||||||||||||||||
Patient hypotensive despite epinephrine? | Yes | ||||||||||||||||||||||||||||||||
No | <left> ❑ Establish IV access ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins ❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </left> | ||||||||||||||||||||||||||||||||
Secondary therapy after epinephrine (evidence not clear) H1 antihistaminics: Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children H2 antihistaminics: Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM | |||||||||||||||||||||||||||||||||
Observe the patient for biphasic anaphylaxis Total period of observation depends on a) clinical condition b) patients access to emergency care setting from home Provide auto-injectable epinephrine and action plan for future events at discharge | |||||||||||||||||||||||||||||||||